Effects of Fluvoxamine on Cognitive Function in Outpatients with Depression in Remission: Results of an Open-Label Pilot Study

Abstract

A prospective, non-comparative, single-centre, single-group study was conducted in 50 adult patients with currently remitted recurrent depressive disorder according to the criteria of the International Classification of Diseases, 10th revision in order to assess changes in cognitive function during preventive therapy with fluvoxamine. Responses to therapy were evaluated using the Stroop Color and Word Test as the primary efficacy outcome. The revised Addenbrooke's Cognitive Examination, Frontal Assessment Battery, Hamilton Rating Scale for Depression and Social Adaptation Self-evaluation Scale were used as secondary indices. Fluvoxamine was administered at doses of 50-150 mg/day for 24 weeks. Fluvoxamine therapy was associated with a range of 'pro-cognitive' responses that resulted in improvement in executive functions, including improved voluntary regulation of inhibitory control and restoration of verbal fluency. No dose relation was apparent for these effects. The incidence of treatmentrelated adverse events was low and no serious or severe events were recorded. These findings indicate that further studies of fluvoxamine are warranted and feasible to characterize possible beneficial effects on cognitive processes in patients with depression.

Depressive disorders and their pharmacotherapy in routine clinical practice

“…Согласно данным многочисленных клинических исследований и метаанализов, СИОЗС, СИОЗСН и вортиоксетин способствуют улучшению когнитивных показателей у пациентов с депрессией [48][49][50][51]. Результаты нескольких открытых исследований указывают на положительное влияние флувоксамина на когнитивные функции при терапии депрессии, связанное с его высоким аффинитетом к сигма-1-рецепторам [52][53][54][55], тогда как применение трициклических антидепрессантов может приводить к ухудшению когнитивных показателей в связи с наличием у них антихолинергического действия [56]. Требуются дополнительные крупные исследования для сравнения степени влияния различных видов психофармакотерапии на когнитивные симптомы.…”

Fluvoxamine Ameliorates the Damage to the Neuro-Behavioral Status of Rats Caused by the Administration of Valproic Acid by Preventing Cognitive Memory Deficits and Decreased Hippocampal Cellular Proliferation

“…It has also been shown to reverse cognitive impairments. Fluvoxamine was discovered to increase nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells via sigma-1 receptor agonism [ 9 , 10 ].…”